Department of Cardiology, Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Taipei, Taiwan.
Department of Surgery, Chang Gung Memorial Hospital, Taipei, Taiwan.
Int J Obes (Lond). 2019 May;43(5):1019-1025. doi: 10.1038/s41366-018-0248-1. Epub 2018 Nov 20.
BACKGROUND/OBJECTIVES: Asprosin is a novel fasting-induced glucogenic and orexigenic protein hormone. The clinical function of asprosin in obesity is currently unknown. This study investigated the association between asprosin abundance and the outcome of bariatric surgery.
SUBJECTS/METHODS: Patients with body mass index more than 35 kg/m were recruited for the Obesity and Clock for Elegant Aging Registry in 2011-2016. Body weight changes, blood sugar, and asprosin were assessed in 117 patients receiving bariatric surgery and 57 non-obese subjects as normal control. Primary outcomes of excess weight loss percentage at 6 months after bariatric surgery were determined at follow-up.
Asprosin levels were significantly higher in obese patients than in non-obese subjects (2360 ± 5094 vs. 307 ± 832 ng/ml, p < 0.0001). Multivariate analyses showed a significant association of asprosin abundance with excess body weight loss percentage at 6 months after surgery (p < 0.0001). After adjusted for age, sex, smoking, HbA1c, cholesterol, and triglyceride, serum asprosin level was the only independent predictor of 6 months excess weight loss percentage after bariatric surgery. Asprosin levels decreased significantly 6 months after bariatric surgery (162.2 ± 169.1 ng/ml). Furthermore, there was no association between asprosin and serum glucose levels in our study.
This study provides novel evidence that higher asprosin concentrations before bariatric surgery were associated with the weight reduction magnitude at 6 months after surgery. Further studies are warranted to investigate whether asprosin has direct functions to modulate body weight regulation in humans after bariatric surgery.
背景/目的：Asprosin 是一种新发现的空腹诱导的产糖和食欲素蛋白激素。Asprosin 在肥胖中的临床功能尚不清楚。本研究探讨了 asprosin 丰度与减肥手术结果之间的关系。
受试者/方法：2011-2016 年，我们招募了肥胖症和时钟优雅老化登记处的 BMI 大于 35kg/m2 的患者。在接受减肥手术的 117 例患者和 57 例非肥胖对照者中，评估了体重变化、血糖和 asprosin。在随访中确定了减肥手术后 6 个月的超重减轻百分比的主要结果。
肥胖患者的 asprosin 水平明显高于非肥胖者（2360±5094 vs. 307±832ng/ml，p<0.0001）。多变量分析显示，asprosin 丰度与手术后 6 个月的超重减轻百分比有显著相关性（p<0.0001）。在校正年龄、性别、吸烟、HbA1c、胆固醇和甘油三酯后，血清 asprosin 水平是减肥手术后 6 个月超重减轻百分比的唯一独立预测因素。减肥手术后 6 个月，血清 asprosin 水平显著下降（162.2±169.1ng/ml）。此外，我们的研究中 asprosin 与血清葡萄糖水平之间没有关联。
本研究提供了新的证据，表明减肥手术前较高的 asprosin 浓度与手术后 6 个月的减重幅度相关。需要进一步的研究来探讨 asprosin 是否在减肥手术后直接调节人体的体重调节。
